Prokidney Corp

prokidney.com

What Do They Do?

Develops a personalized cell therapy made from patients’ kidney cells for people with advanced chronic kidney disease and diabetes.

How Do They Make Money?

It has not generated revenue from product sales; its reported revenue comes from leasing activities under existing lease agreements for two buildings in Winston-Salem.

FY2025 revenue

Do Revenues Turn Into Profits?

No. It lost $69M in FY2025.

Operating income, FY2025

−18478% of revenue

▼ −10% (Loss) vs FY2024 (−$183.7M, −241679%)

Net income, FY2025

−7725% of revenue

▲ +13% (Loss) vs FY2024 (−$61.2M, −80508%)

Free cash flow, FY2025

−15153% of revenue

▼ −13% (Loss) vs FY2024 (−$155.9M, −205079%)

How Are They Changing?

Since the FY2025 annual report

Latest quarter: Q2 FY2026, the three months to Jun 30, 2026

Revenue: ▼ −32%; vs $221K in Q2 FY2025
Net income: ▲ +72% (Loss); vs −$16.6M in Q2 FY2025

Development program focus The earlier report described REACT for diabetic kidney disease and congenital kidney conditions, alongside preclinical programs using genetically modified kidney cells. The latest report centers on rilparencel for advanced kidney disease and diabetes, with additional candidates framed as future research.

Who Do They Compete With?

Competes with Janssen Pharmaceuticals, AstraZeneca, Bristol-Myers Squibb, Boehringer Ingelheim, Eli Lilly, Bayer, and Novo Nordisk

Comments